Skip to main content
Premium Trial:

Request an Annual Quote

Arcturus Adds Second ATTR Program to Pipeline

Premium

NEW YORK (GenomeWeb) – Arcturus Therapeutics has announced that it has added a second drug candidate to its transthyretin-mediated amyloidosis (ATTR) program.

ATTR disease is caused by mutations in the transthyretin (TTR) gene, which triggers the accumulation of abnormal amyloid proteins in the body. Previously, Arcturus announced that it is developing an ATTR drug designed to silence both the wild-type and mutant forms of the gene, which would be used for patients with a form of ATTR that primarily damages heart tissue called familial amyloidotic cardiomyopathy (FAC).

This week, the company announced new preclinical data showing that its RNAi molecules, which incorporate proprietary unlocked nucleobase analog modifications, are capable of silencing mutant TTR while leaving the wild-type form intact.

Based on these data, Arcturus has added a mutant allele-specific ATTR candidate to its drug-development roster. According to a company official, the new compound will be developed for another form of ATTR called familial amyloidotic polyneuropathy, or FAP, which is characterized by damage to the peripheral nervous system.

Arcturus has previously stated that its FAC drug is slated to enter the clinic in early 2015.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.